The Trump administration is proposing significant reforms to the hospital drug discount program, a $100 billion initiative designed to reduce pharmaceutical costs. These regulatory changes aim to reshape how healthcare facilities access discounted medications while addressing spending concerns. The proposed modifications have sparked intense debate among stakeholders, including hospital administrators, pharmaceutical companies, and policymakers, regarding the program's future structure and its impact on patient affordability and healthcare economics.

Summary auto-generated by AI from the original publisher's content. Editorial standards.